Articles tagged with Metastasis
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Researchers at Osaka Metropolitan University assessed target genes in canine hepatocellular carcinoma (HCC) to develop molecular targeted therapies. The study identified potential gene targets, including PDGFB, which may improve treatment options for unresectable HCC.
A new study reveals that microglia can be reprogrammed from a tumor-promoting state to one that strengthens antitumor responses, reducing brain metastases growth and enhancing immunotherapy responses. Researchers identified a key signaling pathway that, when blocked, reverses the protumoral function of microglia.
Researchers at KAIST have discovered a molecular switch that can induce cancer reversal by capturing the moment of critical transition before normal cells become irreversibly cancerous. The technology uses single-cell RNA sequencing data and computer simulation analysis to identify the molecular switch.
The ACC Advancing the Cardiovascular Care of the Oncology Patient conference will provide clinicians with tools to improve cardiovascular care of cancer patients. Key sessions will include discussions on pulmonary tumor thrombotic microangiopathy, AI and technology in cardio-oncology.
The Neuro-Oncology Translational Research Training Program aims to bridge laboratory discoveries and clinical applications in neuro-oncology, targeting glioblastoma and brain metastases. The program provides predoctoral and postdoctoral trainees with cutting-edge lab experience and mentorship across multiple disciplines.
A new study published in Neuro-Oncology found that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously thought. The study suggests that doctors may need to rethink current screening guidelines for detecting brain metastasis in patients without symptoms.
Researchers at Rice University's Synthesis X Center and MD Anderson Cancer Center are developing a light-induced brain delivery platform to improve drug delivery across the blood-brain barrier for treating brain metastasis. The goal is to enhance survival rates and transform the standard of care for this deadly form of cancer.
A new study published in Nature Medicine shows a promising approach to preventing metastases in breast cancer patients. Researchers found that administering digoxin reduced circulating tumour cell clusters by an average of 2.2 cells, significantly decreasing the risk of metastasis.
Researchers have developed a novel stem cell treatment strategy for leptomeningeal brain metastasis, a severe form of metastatic brain cancer. The new therapy, which combines allogeneic dual stem cells with oncolytic herpes simplex virus and single chain variable fragment of anti-PD-1, shows promise in preclinical models.
A new combination therapy combining systemic interferon-I with local imiquimod application showed promising results in treating melanoma and breast cancer. The therapy activated the adaptive immune system to fight distant metastases, reducing tumor relapses and increasing sensitivity to checkpoint inhibitors.
Researchers have long puzzled over how filopodia, finger-like protrusions on migratory cells, are formed. A new study from Rockefeller University reveals the atomic-level structure of these bundles, providing insights into their function and potential applications in cancer treatment. The discovery may help refine therapies already in ...
Researchers developed an AI model to detect brain cancer spread in surrounding tissue using MRI scans, showing 85-per-cent accuracy. This non-surgical method offers insights into patients' cancer without aggressive surgery, potentially improving treatment and survival.
Researchers have identified a 177-gene signature common to metastasis across cancers, allowing for personalized risk assessment and potential therapies. The discovery could lead to broader treatment options, faster drug access, and improved patient outcomes.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
Scientists cultivate stable tumor organoids directly from blood samples of breast cancer patients, revealing a molecular signaling pathway that ensures cancer cell survival and resistance to therapy. The team develops an approach to specifically eliminate these tumor cells in lab experiments.
The study identified a modified imaging approach and volumetric measurements as more accurate in predicting survival compared to other methods. These approaches worked well even for small tumors, suggesting they should be included in future studies.
A new experimental technique has developed a molecular flashlight to monitor molecular changes in the brain caused by cancer and other neurological pathologies. The technique uses vibrational spectroscopy to illuminate nerve tissue, allowing for the analysis of molecular changes caused by tumours or injuries.
Researchers developed biodegradable polymeric nanoparticles that selectively target cancer cells with two approved drug pairs for skin and breast cancers. The treatment showed significantly enhanced therapeutic effects, reduced tumor size, and prolonged median survival in mice.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
The PATINA study demonstrates that palbociclib improves progression-free survival (PFS) in patients with HR+, HER2+ metastatic breast cancer, with a median PFS of 44.3 months. This represents an extension in median PFS of over 15 months compared to anti-HER2 therapy and endocrine therapy alone.
The study found a significant increase in late-stage breast cancer diagnoses among U.S. women, with annual percentage increases of up to 2.9% between 2004 and 2021. The researchers attribute the trend to factors such as lack of national screening programs, inconsistent guidelines, and increasing obesity rates.
A study published in Cell found a common variant of the PCSK9 gene increases the risk of breast cancer metastasis by 22% compared to those without it. Researchers propose using an antibody targeting PCSK9 to suppress this variant and reduce metastatic disease.
A study led by UF Health Cancer Center researchers found that a toxin in the bacteria Campylobacter jejuni accelerates the spread of colorectal tumors. The findings could lead to new tools for detecting metastatic colorectal cancer early, ultimately helping determine patients who need more aggressive treatments.
A study found that postmenopausal women with low-risk tumors experience a long-term benefit from anti-hormonal treatment of at least 20 years, while younger women do not. The researchers highlight the need for new markers to predict long-term risk and benefit in younger patients.
Researchers found that tumor cell secreted DNA in extracellular vesicles acts as a 'danger' signal to activate an anti-tumor response in the liver, reducing liver metastasis risk. The discovery improves understanding of cancer progression and anticancer immunity.
A groundbreaking study explores the therapeutic potential of tumor-infiltrating lymphocytes (TILs) derived from metastatic lymph nodes in advanced cervical cancer. The innovative approach demonstrates a manageable safety profile, while also showing promise for improving treatment efficacy.
Researchers studied ovarian cancer cell migration patterns on soft and stiff surfaces, finding that epithelioid cells are more migratory than mesenchymal cells on stiffer matrices. The study used a novel software toolkit to analyze cell behavior over time, revealing a unique 'slip' movement pattern in epithelioid cells.
Researchers at The Wistar Institute have discovered a new combination therapy approach that shrinks tumors and improves survival rates in metastatic ovarian cancer. By activating myeloid cells, the treatment overcomes immunosuppression around tumors and makes them more receptive to chemotherapy.
Epigenetic changes, driven by oxidative stress, facilitate tumor metastasis through EMT, ECM remodeling, and CTCs survival. Novel therapeutic strategies combining oxidative stress modulators and epigenetic drugs show promise in combating metastasis.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
The Wyss Institute's iNodes team has been awarded an ARPA-H Sprint for Women's Health to develop implantable immune organs for treating ovarian cancer. The iNodes concept is based on the formation of lymphoid organs in tumors, which can be reprogrammed to attack cancer cells and retain a long-term immune memory.
A collaborative study led by Dr. Julie St-Pierre at the University of Ottawa found that promoting mitochondrial elongation in cancer cells hobbles their ability to metastasize. The research team identified a common signature that could help determine which pathways lead to decreased metastasis.
Researchers document remarkable response to pembrolizumab in patient with metastatic adenosquamous pancreatic cancer (ASCP) and KRAS G12C mutation. The study highlights potential shift in treatment of ASCP, a rare form of pancreatic cancer traditionally underserved by current therapies.
A new MSK study has identified patterns in how cancer cells reprogram themselves during metastasis, providing new details on cellular plasticity. The research team compared samples from patients with advanced colorectal cancer and found clear patterns in the way metastatic cells change their identity to access early cell states.
Researchers developed a method to assess which patients with metastatic triple-negative breast cancer can benefit from immunotherapy. The tool uses predictive biomarkers and machine learning-based approaches to identify patients who are likely to respond to treatment.
A remarkable clinical and metabolic response is reported in a metastatic BRAF V600E-mutated glomangiosarcoma treated with encorafenib and binimetinib. The combination of BRAF and MEK inhibitors achieves a long-lasting complete morpho-metabolic response in the patient.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers created a 3D-printed model to mimic the conditions that spur cancer cells' spread, allowing them to visualize this process in real-time. The model revealed a mechanism where low oxygen levels promote metastasis through lowering pH levels.
Researchers at Weill Cornell Medicine identified a unique enzyme called FTSJ1 that enables melanoma cells to escape oxidative stress and spread. By targeting this enzyme, therapies may prevent or treat metastasis with minimal side effects.
Researchers found that physically fitter patients with metastatic lung cancer live longer and respond better to chemotherapy. The study identified biomarkers in blood plasma that can indicate which patients are most likely to respond to treatment.
Researchers develop physiologically relevant model to investigate breast cancer bone metastasis, holding promise for predicting risk and developing new treatments.
Researchers reported a complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer patient with brain metastases. The patient achieved overall survival of 87 months and progression-free survival of 73 months after treatment sequencing.
Researchers found that ApoE protects melanoma cells from ferroptosis by increasing antioxidant capacity and neutralizing lipids. This discovery highlights the APOE gene as a critical factor in melanoma cell survival, potentially opening new avenues for treatment.
A recent study published in Nature Cancer has discovered that cancer cells exhibit opposing pro and antitumor programs, with the former promoting metastasis and the latter combating tumor growth. This finding opens new avenues for therapeutic strategies to target highly aggressive and therapy-resistant tumors.
Researchers have engineered probiotic bacteria to educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines. The bacterial vaccine proved more efficacious than peptide-based therapeutic cancer vaccines in studies using mouse models of advanced colorectal and melanoma cancers.
Research highlights molecular chaperones' role in maintaining tumor suppressor stability and functional integrity. This understanding is crucial for developing targeted therapies for multiple cancers.
Researchers at Johns Hopkins Medicine developed a potential novel treatment for breast cancer bone metastasis using RK-33, which targets and inhibits the protein DDX3. The drug successfully eliminated breast cancer bone metastases in lab models by controlling cancer cell growth and proliferation.
Researchers at the Hebrew University of Jerusalem have developed a highly selective inhibitor for Matrix Metallopeptidase 7 (MMP7), an enzyme crucial for cancer spread and progression. The novel peptide D'20 demonstrates remarkable stability and selectivity, targeting MMP7 while leaving similar enzymes unaffected.
A research team at IIT has identified a molecular signature in triple-negative breast cancer cells that can predict the formation of metastases and chemotherapy resistance. The study used single-cell sequencing to track the evolution of cancer cells over time, revealing key epigenetic features involved in tumor development.
A non-invasive blood test measuring circulating tumor cells can predict treatment response, disease progression, and overall survival in men with metastatic prostate cancer. Patients with more CTCs had shorter median survival lengths and a greater risk of death.
Researchers at Montefiore Einstein Comprehensive Cancer Center have discovered a natural immune mechanism in mice that stops escaped cancer cells from developing into tumors elsewhere in the body. Alveolar macrophages recognize and interact with disseminated cancer cells, producing signals that keep them dormant.
Researchers identified AM-101 as a potential new way to enhance radiation therapy for patients with lung cancer that has spread to the brain. The drug's ability to activate GABA(A) receptors increases autophagy in lung cancer cells, making them more sensitive to radiation treatment.
Two UCF cancer researchers, Alicja Copik and Debbie Altomare, have received $100,000 grants from the Florida Breast Cancer Foundation to develop new treatments for breast cancer. They focus on enhancing natural killer cells to fight cancer and harnessing the body's immune system to create new therapies.
Researchers at CNIO propose a new treatment for brain metastasis by targeting pro-tumour astrocytes with immunotherapy. They identified TIMP1 as a biomarker to predict when immunotherapy is effective, and a clinical trial is underway to test the therapeutic efficacy of silibinin inhibition.
Researchers propose reevaluating nomenclature for low-grade prostate cancer, a condition that rarely metastasizes or causes symptoms. This shift aims to balance detection with treatment to reduce harms of overdiagnosis and overtreatment.
A pooled analysis of three large, phase III clinical trials found that more than 40% of brain metastases patients can fully reverse cognitive losses with conformal radiation techniques. Recovery was more likely for those treated with highly targeted radiation compared to standard whole-brain treatment.
Researchers at Cold Spring Harbor Laboratory create a roadmap of how prostate cancer spreads throughout the body, showing that aggressive cells seed cancer's rare migrations to bones, liver, lungs, and lymph nodes. The new technology offers a clearer picture of cancer spread and could lead to more targeted therapeutics.
The CheckMate 067 trial showed that combining nivolumab and ipilimumab improved outcomes for metastatic melanoma patients, with a median survival time over six years. Long-term follow-up found no new safety signals for the treatment, and metastatic melanoma survivors become increasingly likely to die of other causes as they age.